Horizon Pharma acquires Crealta Holdings for $510 million and with it Krystexxa, a leading treatment for gout
Horizon Pharma announced it has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash. The acquisition, according to Horizon:
- Leverages rheumatology infrastructure and 41-person sales force currently promoting Rayos and Pennsaid 2% to rheumatologists.
- Adds a biologic medicine in an orphan disease with strong intellectual property protection through 2027 and further diversifies net sales
- Reinforces focus of Company's long-range plan where orphan business is expected to be approximately 60% of net sales in 2020.
The acquisition gives Horizon access to Krystexxa (pegloticase) is the first and only FDA-approved medicine for chronic refractory gout, which is an orphan disease and a type of arthritis that occurs when uric acid build up in the blood remains high and inflammation persists even after treatment with conventional therapies. According to estimates, chronic refractory gout impacts approximately 50,000 people in the United States. Since its FDA approval in 2010, between 4,000 and 5,000 patients have been treated with Krystexxa.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins